| Name | Iopamidol |
| Description | Iopamidol (SQ-13396) is a benzenedicarboxamide compound. It has a role as a radioopaque medium, an environmental contaminant and a xenobiotic. |
| Cell Research | Chondrocytes are plated on 96 well plates at a density of 1 x 106 cells/cm2 . After overnight incubation in standard tissue culture conditions, contrast agents (including iopamidol) are introduced to wells in varying concentrations. Following 16 hour incubation with PBS and contrast agents, chondrocyte viability is assessed using the Live/Dead stain kit and quantified using the CellTiter-Glo Luminescent Cell Viability Assay. (Only for Reference) |
| In vitro | Iopamidol significantly decreases the rate of atrial contraction to a greater extent than either formulation of iodixanol. Iopamidol decreases papillary muscle force development more than the sodium formulation of iodixanol[3]. |
| In vivo | Iopamidol increases systolic blood pressure (SBP), mean arterial pressure (MAP), and peak left ventricular pressure (LVP). Iopamidol increases LVP and LV end diastolic pressure to a greater extent than the cationic formulation of iodixanol. Thus iopamidol affects cardiovascular parameters more than iodixanol[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : 92 mg/mL (118.39 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (4.25 mM), Sonication is recommended.
DMSO : 247.5 mg/mL (318.5 mM), Sonication is recommended.
|
| Keywords | X-Ray | SQ13396 | SQ 13396 | nonionic | Iopamidol | iodinated | Inhibitor | inhibit | diagnostic | contrast | CEST | B15000 | B 15000 | agent |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Cardiotoxicity Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |
United States
